US Pharmaceutical Market Growth Report
If you would like to purchase the full report, please contact us here. The average number of pages for the report is 100-200 pages.
US Pharmaceutical Market Growth Report
Meta Description: A comprehensive analysis of the US pharmaceutical market projecting growth from $610B (2025) to $850B (2030), covering specialty drugs, IRA price negotiations, biosimilars, and R&D productivity.
Title Tag: US Pharmaceutical Market Growth Report 2030 | IRA Impact, Biosimilar Expansion & Specialty Drug Dominance
Executive Summary
The US pharmaceutical market is the largest and most profitable globally, but it faces unprecedented pressure from the Inflation Reduction Act’s (IRA) drug price negotiation provisions. This report provides a definitive analysis of market size, therapeutic categories, pricing trends, biosimilar adoption, and R&D productivity through 2030. Our research projects the US pharma market to grow from approximately $610 billion in 2025 to $850 billion by 2030, representing a compound annual growth rate (CAGR) of 6.8%. This growth is slower than the 8–10% historical average due to IRA price negotiations, increased biosimilar competition, and the patent cliff for blockbuster immunology drugs (Humira, Stelara, Enbrel). Specialty drugs (oncology, immunology, neurology, rare diseases) now represent 55% of spending, projected to reach 65% by 2030. The IRA’s drug price negotiation program begins in 2026 with 10 Part D drugs, expanding to 20 drugs annually by 2029. CMS estimates $100 billion in Medicare savings over 10 years. Biosimilar adoption is accelerating, with annual savings projected to reach $100 billion by 2030 as 20+ biologics lose exclusivity. GLP-1 agonists for diabetes and obesity (Ozempic, Mounjaro, Wegovy) have become the best-selling drug class in US history, with combined 2025 sales exceeding $50 billion. This report analyzes therapeutic categories, IRA impact, biosimilar penetration, R&D productivity, and provides strategic recommendations for manufacturers and payers.
1. Market Size and Therapeutic Category Forecast
The US pharmaceutical market outperforms all other global regions in both per capita spending ($1,500 vs. OECD average $600) and innovation output (45% of global novel drug launches).
Table 1: US Pharmaceutical Market Forecast by Category (2025–2030)
| Category | 2025 ($B) | 2027 ($B) | 2030 ($B) | CAGR (%) | Description |
|---|---|---|---|---|---|
| Specialty Drugs | $335 | $395 | $510 | 8.8% | Biologics, gene therapy, oncology |
| Primary Care Drugs | $185 | $195 | $230 | 4.5% | Generics, mature brands |
| Biosimilars | $30 | $55 | $80 | 21.7% | Off-patent biologics |
| GLP-1 Agonists | $50 | $65 | $80 | 9.9% | Diabetes/obesity (counted within specialty) |
| Vaccines | $10 | $12 | $15 | 8.4% | Preventative |
| Total | $610 | $722 | $850 | 6.8% | – |
Table 2: Top 10 Drug Products by US Sales (2025)
| Rank | Drug | Manufacturer | Indication | 2025 Sales ($B) | IRA Negotiation Eligible |
|---|---|---|---|---|---|
| 1 | Keytruda (pembrolizumab) | Merck | Oncology (various) | $25 | 2028 (Part B) |
| 2 | Ozempic/Wegovy (semaglutide) | Novo Nordisk | Diabetes/obesity | $22 | 2027 (Part D) |
| 3 | Mounjaro/Zepbound (tirzepatide) | Eli Lilly | Diabetes/obesity | $18 | 2029 (Part D) |
| 4 | Humira (adalimumab) | AbbVie | Immunology (RA, etc.) | $12 | Already negotiated (biosimilars) |
| 5 | Eliquis (apixaban) | BMS/Pfizer | Anticoagulation | $11 | 2026 (Part D) |
| 6 | Darzalex (daratumumab) | J&J | Multiple myeloma | $10 | 2030 (Part B) |
| 7 | Stelara (ustekinumab) | J&J | Psoriasis, Crohn’s | $9 | 2027 (Part D) |
| 8 | Opdivo (nivolumab) | BMS | Oncology | $8 | 2029 (Part B) |
| 9 | Trulicity (dulaglutide) | Eli Lilly | Diabetes | $7 | 2027 (Part D) |
| 10 | Enbrel (etanercept) | Amgen | Immunology | $6 | 2029 (Part D) |
2. Inflation Reduction Act (IRA) Drug Price Negotiation
The IRA’s drug price negotiation provisions (Section 11001) represent the most significant change to Medicare Part D since its 2006 creation. The law gives CMS authority to negotiate prices for high-spend, no-generic drugs after a specified exclusivity period.
Table 3: IRA Drug Price Negotiation Timeline and Impact
| Year | Number of Drugs | Eligible Drugs | Est. Savings ($B) | Eligible Categories |
|---|---|---|---|---|
| 2026 | 10 | $50B+ annual spend | $3.5 | Part D (oral, self-administered) |
| 2027 | 15 | $75B+ annual spend | $5.0 | Part D + Part B (infused) |
| 2028 | 15 | $100B+ annual spend | $6.0 | Part D + Part B |
| 2029 | 20 | $150B+ annual spend | $8.0 | Part D + Part B |
| 2030+ | 20 | $200B+ annual spend | $10.0+ | Part D + Part B |
Negotiation Mechanics:
- Eligibility: Drugs with 9 years (small molecule) or 13 years (biologic) since FDA approval, no generic/biosimilar competition, among 50 highest-spend Medicare drugs.
- Maximum Fair Price (MFP): Cannot exceed 75% of average manufacturer price for small molecules (12–16 years post-approval) or 65% for biologics (12–16 years). For older drugs (16+ years), MFP cannot exceed 40% of AMP.
- Non-compliance Penalty: Excise tax starting at 65% of sales, rising to 95% for manufacturers that refuse to negotiate.
Selected Drugs in First Negotiation Round (2026): Eliquis (BMS/Pfizer), Jardiance (Boehringer/Lilly), Xarelto (J&J), Enbrel (Amgen), Stelara (J&J), Entresto (Novartis), Farxiga (AstraZeneca), Imbruvica (AbbVie/J&J), Januvia (Merck), Novolog (Novo Nordisk).
Industry Response: Five manufacturers (BMS, J&J, Merck, Novo Nordisk, AstraZeneca) have filed lawsuits challenging the negotiation mechanism as unconstitutional (Fifth Amendment taking, First Amendment compelled speech). Supreme Court review is likely in 2026.
3. Biosimilar Market Expansion
Biosimilars are biological products highly similar to an already-approved reference product. They offer lower cost (typically 15–50% discount) but require extensive analytical and clinical testing.
Table 4: Major Biologic Patent Expiries and Biosimilar Entry (2025–2030)
| Reference Product | Manufacturer | 2025 US Sales ($B) | Patent Expiry | Biosimilar Entry | Projected Discount |
|---|---|---|---|---|---|
| Humira (adalimumab) | AbbVie | $12 | 2023 | 2023 (10+ entrants) | 80%+ |
| Stelara (ustekinumab) | J&J | $9 | 2025 | 2025–2026 | 30–40% |
| Keytruda (pembrolizumab) | Merck | $25 | 2028 | 2028–2029 | 15–25% |
| Opdivo (nivolumab) | BMS | $8 | 2028 | 2028–2029 | 15–25% |
| Darzalex (daratumumab) | J&J | $10 | 2029 | 2029–2030 | 15–20% |
| Eylea (aflibercept) | Regeneron | $6 | 2026 | 2026–2027 | 30–40% |
| Avastin (bevacizumab) | Roche | $2 | 2019 | Multiple | 60%+ |
| Rituxan (rituximab) | Roche | $2 | 2018 | Multiple | 60%+ |
Biosimilar Adoption Barriers:
- Interchangeability designation: Only 8 biosimilars have FDA interchangeability status (pharmacist can substitute without prescriber involvement). Most states require 1–2 years of post-approval data for interchangeability.
- Rebate traps: Manufacturers offer large rebates on reference products to keep them on formulary. A biosimilar must offer 40–50% list price discount to overcome rebate disadvantage.
- Physician and patient inertia: Biologics are prescribed for chronic conditions; switching requires patient and physician agreement.
Biosimilar Savings Forecast: By 2030, biosimilars will save the US healthcare system $100 billion annually, with $50 billion from adalimumab biosimilars alone.
4. GLP-1 Agonist Revolution
GLP-1 receptor agonists (semaglutide, tirzepatide) have become the best-selling drug class in US history. Initially approved for type 2 diabetes, they are now approved for obesity and being studied for cardiovascular disease, sleep apnea, heart failure, and Alzheimer’s.
Table 5: GLP-1 Market Dynamics (2025–2030)
| Metric | 2025 | 2027 | 2030 |
|---|---|---|---|
| US sales ($B) | $50 | $65 | $80 |
| Number of patients (M) | 12 | 18 | 25 |
| Average monthly price ($) | $1,000 | $900 | $750 |
| Medicare Part D coverage | Yes (diabetes only) | Yes (obesity under review) | Likely full coverage |
| Employer coverage (%) | 45% | 60% | 75% |
| Pipeline candidates | 15 | 10 | 5 |
Key Products:
- Ozempic/Wegovy (Novo Nordisk, semaglutide): 15% weight loss (Wegovy). Diabetes (Ozempic) and obesity (Wegovy). Supply constraints expected through 2026.
- Mounjaro/Zepbound (Eli Lilly, tirzepatide): 20–22% weight loss (Zepbound). Dual GIP/GLP-1 agonist. Superior efficacy to semaglutide.
- Retatrutide (Eli Lilly, Phase 3): Triple agonist (GIP/GLP-1/glucagon). 24% weight loss in Phase 2.
- Oral semaglutide (Novo Nordisk, Rybelsus): Lower efficacy than injectable but convenient. Being studied for obesity.
Supply Chain Constraints: Manufacturing capacity is the primary limitation. Novo Nordisk and Eli Lilly are investing $15 billion+ in new production facilities, but full capacity is not expected until 2027–2028.
Cost and Coverage: Monthly list price is $1,000–$1,300 for obesity indications. Medicare cannot cover obesity drugs under current law (2003 prohibition). Legislation to repeal this prohibition (Treat and Reduce Obesity Act) has bipartisan support but has not passed. Employer coverage is expanding, with 45% of large employers covering GLP-1s for obesity (up from 25% in 2023).
5. R&D Productivity and Pipeline Analysis
R&D productivity has improved significantly over the past decade, driven by better target selection, biomarker-driven trials, and regulatory expedited pathways.
Table 6: R&D Productivity Metrics (2015–2025)
| Metric | 2015 | 2020 | 2025 |
|---|---|---|---|
| Cost to develop a new drug ($B) | $2.6 | $2.2 | $1.8 |
| Clinical trial success rate (Phase 1 to approval) | 8% | 12% | 14% |
| Average development time (years) | 12 | 10 | 9 |
| NMEs approved annually (FDA) | 45 | 53 | 55 |
| Orphan drug share of approvals | 35% | 45% | 45% |
| Accelerated approval share | 10% | 25% | 22% |
Pipeline by Phase (2025):
- Phase 1: 2,500+ assets
- Phase 2: 1,800+ assets
- Phase 3: 600+ assets
- NDA/BLA filed: 120+ assets
Top Pipeline Categories:
- Oncology (35% of pipeline) – ADCs, bispecifics, cell therapies
- Neurology (15%) – Alzheimer’s, Parkinson’s, ALS
- Immunology (12%) – New targets beyond TNF and IL-23
- Metabolic (10%) – Next-gen GLP-1, PCSK9, gene silencing
- Rare diseases (20%) – Gene therapy, enzyme replacement
- Other (8%)
AI in Drug Discovery: Generative AI is transforming early-stage discovery. Companies with AI-discovered assets in clinical trials include Insilico Medicine (IPF, Phase 2), Exscientia (oncology, Phase 2), Recursion (neuro, Phase 2), and Schrödinger (oncology, Phase 1). The first AI-discovered drug approval is expected by 2028–2029.
6. Challenges and Future Outlook
Challenges:
- IRA price negotiation: Estimated 15–25% revenue reduction for affected drugs by 2030.
- Patent cliff: $200 billion in sales facing loss of exclusivity by 2030.
- Pricing transparency laws: State laws (California, Colorado, Nevada) require advance notice of price increases >10% annually.
- Drug shortages: Record 300+ active shortages in 2024, primarily generics (chemotherapy, antibiotics, ADHD medications).
- PBMI market concentration: Three PBMs (CVS Caremark, Express Scripts, OptumRx) control 80% of prescription volume.
Future Outlook (2030):
- First curative in vivo gene editing therapy approved
- GLP-1s become best-selling drug class ($100B+ global sales)
- 50+ gene and cell therapies on market
- First AI-discovered drug approved
- IRA negotiation expanded to Part B drugs (infused) at lower exclusivity periods (7–9 years)
FAQ
Q1: What is the projected US pharmaceutical market size in 2030?
A1: $850 billion.
Q2: What percentage of spending do specialty drugs represent in 2025?
A2: 55%.
Q3: How many drugs will CMS negotiate prices for in 2026?
A3: 10 drugs.
Q4: What is the estimated annual biosimilar savings by 2030?
A4: $100 billion.
Q5: Which drug class is the best-selling in US history, with 2025 sales exceeding $50 billion?
A5: GLP-1 agonists (Ozempic, Mounjaro, Wegovy, etc.).
Q6: What is the non-compliance penalty for manufacturers refusing IRA negotiation?
A6: Excise tax starting at 65% of sales, rising to 95%.
Q7: Which drug will have 10+ biosimilar entrants after its 2023 patent expiry?
A7: Humira (adalimumab).
Q8: What is the average cost to develop a new drug in 2025?
A8: $1.8 billion.
Q9: How many active drug shortages were reported in 2024?
A9: Over 300.
Q10: Name the three largest PBMs controlling 80% of prescription volume.
A10: CVS Caremark, Express Scripts, OptumRx.
If you would like to purchase the full report, please contact us here. The average number of pages for the report is 100-200 pages.
